Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Papageorgiou
Sotirios G
SG
Pappa
Vasiliki
V
Economopoulou
Christina
C
Tsirigotis
Panagiotis
P
Konsioti
Frida
F
Ionnidou
Eleni-Dikaia
ED
Chondropoulos
Spyros
S
Vasilatou
Diamantina
D
Papageorgiou
Efstathios
E
Economopoulos
Theofanis
T
Dervenoulas
John
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016543:Central Nervous System Neoplasms / Q000556:secondary*; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib